Skip to main content

Amdinocillin use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on Dec 21, 2023.

Amdinocillin Levels and Effects while Breastfeeding

Summary of Use during Lactation

Amdinocillin (pivmecillinam; the pivaloyl ester of mecillinam) is not commercially available in the United States, but is marketed internationally. Limited information indicates that amdinocillin produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Monitor the breastfed infant for diarrhea and thrush.

Drug Levels

Maternal Levels. Four women who were 4 or 6 days postpartum were given a single 100 mg dose of amdinocillin. The drug was not detectable in breastmilk 1 or 3 hours after the dose, although the sensitivity of the assay is unknown.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Seiga K, Minagawa M, Yamaji K, et al. Studies on pivmecillinam. Chemotherapy (Tokyo). 1977;25:347–51. [CrossRef]

Substance Identification

Substance Name

Amdinocillin

CAS Registry Number

32886-97-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Infective Agents, Urinary

Anti-Bacterial Agents

Beta-Lactams

Penicillins

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.